---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-218224"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2026-05-12T12:00:07+00:00"
generated_at: "2026-05-12T12:20:18.531907+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Tenax Q1 net loss $15.7M; cash $118.8M; Phase 3 topline data expected Q3 2026

## Summary
- Net loss of $15.7M for Q1 2026 vs $10.4M in Q1 2025; R&D expense rose to $11.5M from $5.7M.
- Cash and equivalents $118.8M as of March 31, 2026; expected to fund operations through at least Q1 2028.
- Phase 3 LEVEL study fully randomized (>230 patients); topline data anticipated in Q3 2026.
- Appointed Thomas Staab as CFO, Timothy Healey as CCO, and So-Young Kim as EVP Clinical Development.
- Phase 3 LEVEL-2 trial ongoing; enrollment completion expected by end of 2027.

## SEC filing metadata
- accession: 0001193125-26-218224
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2026-05-12T12:00:07+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000119312526218224/0001193125-26-218224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000119312526218224/d91737d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-218224
- JSON: https://secwatch.observer/filing/0001193125-26-218224.json
- Plain text: https://secwatch.observer/filing/0001193125-26-218224.txt

## Key facts
- Earnings Releases
  TENAX THERAPEUTICS, INC. reported the quarter ended March 31, 2026 results: net income $15.7 million.
  - Period: the quarter ended March 31, 2026
  - Net income: $15.7 million
  - Result: reported results
  source text: Tenax Therapeutics reported a net loss of $15.7 million for the first quarter of 2026, compared to a net loss of $10.4 million for the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000119312526218224/0001193125-26-218224-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.